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Genetics and Genomics of Stroke
Novel Approaches
Alison E. Baird, MBBS, PHD
Brooklyn, New York
Evidence for a genetic basis for stroke comes from twin and family studies and from the occurrence of a num-
ber of uncommon monogenic disorders, but the contribution of genetic factors identified for stroke so far is
small. Advances in genetics and genomics may permit new insights. In recent genome-wide association studies,
a number of single-nucleotide polymorphisms have been associated with specific stroke subtypes and major
stroke risk factors such as diabetes and atrial fibrillation. These await replication. Studies of messenger ribonu-
cleic acid expression have also shown promise for the development of genomic signatures for stroke classifica-
tion. Stroke and coronary heart disease share some features of pathophysiology, risk, and treatment, and their
genetic and genomic bases also appear to overlap. (J Am Coll Cardiol 2010;56:245–53) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.051(
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chen the human genome was sequenced in 2003, the
mplications for cardiovascular and stroke medicine—in
erms of the new diagnostic, therapeutic, and preventive
trategies that may ultimately result—were immediately
ecognized (1,2). Genetic and genomic factors appear to
ontribute to all stages of the development of vascular
isease, from predisposition, through risk and subclinical
isease, to overt disease. Although the contribution of
enetic factors identified for stroke is small at present, it is
ery possible that the sequencing of the genome may result
n novel clinical applications, including the development of
iomarkers for stroke.
Strokes result from focal reductions of blood flow to the
rain and are second to coronary heart disease (CHD) in
erms of vascular disease incidence, morbidity, and mortal-
ty. Currently, there are about 795,000 new and recurrent
trokes per year in the U.S. compared with 1,350,000 new
nd recurrent coronary events (3). There is a substantial
dditional burden of asymptomatic cerebrovascular disease.
bout 83% of strokes are due to arterial vascular occlusion
ischemic stroke), and about 17% are due to vascular rupture
hemorrhagic stroke) (4–6).
Many scientific advances have occurred in stroke diagno-
is, treatment, and prevention over the past 10 to 20 years
7,8), such as advances in neurovascular imaging and intra-
enous tissue plasminogen activator therapy, but important
uestions remain unanswered. Modifiable risk factors ac-
ount for only about 60% of the population-attributable risk
rom the Department of Neurology, SUNY Downstate Medical Center, Brooklyn,
ew York. The author has one patent relating to stroke and patents pending for
ntracerebral hemorrhage and vascular disease risk.n
Manuscript received July 16, 2008; revised manuscript received February 2, 2010,
ccepted February 9, 2010.PAR) for stroke (9,10), as opposed to risk factors identified
or CHD, which may account for more than 90% of the
ttributable risk (11). The mechanisms for over 30% of
schemic strokes are not known, even after extensive workup
12–14). Stroke diagnosis is inaccurate in up to 30% of
atients acutely, and it is not possible to reliably distinguish
etween ischemic and hemorrhagic stroke clinically. No
lood-based diagnostic marker has yet been developed for
troke, unlike for acute coronary syndromes; this might be
ecause of issues related to the blood-brain barrier. There is
lso no reliable way to predict which patients will develop
emorrhagic transformation in the brain after thrombolytic
herapy (8).
This review begins with a description of the currently
ecognized genetic factors involved in stroke risk and
tiology: family history, single-nucleotide polymorphisms
SNPs), and monogenic disorders. This is followed by the
rst results that have recently been obtained from genome-
ide association and gene expression and protein expression
rofiling studies—new genomic methodologies that have
een developed over the past decade (Online Appendix).
he genetic and genomic overlap between stroke and CHD
nd other forms of vascular disease is becoming increasingly
pparent, and some examples are provided in the final
ection.
enetic Factors in Stroke Risk and Etiology
enetic factors that are associated with increased stroke risk
re a family history of stroke and a number of SNPs. A
umber of monogenic disorders cause stroke, either as a
rimary manifestation or a secondary manifestation. The
ontribution of these factors has been increasingly recog-
ized over the past 10 to 20 years from findings in twin
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Stroke Genetics and Genomics July 20, 2010:245–53studies (15) and the description
of monogenic disorders such as
cerebral autosomal dominant ar-
teriopathy with subcortical in-
farcts and leukoencephalopathy
(CADASIL) (16). More recently,
it was reported that Fabry disease
accounts for a previously unrec-
ognized proportion of strokes of
undetermined mechanism (i.e.,
cryptogenic stroke) in the young
(17). Evidence for a genetic basis
for stroke has also come from
experimental stroke models (18).
The importance of the accu-
rate classification of stroke type
and subtype needs to be appreci-
ated, because ischemic and hem-
orrhagic strokes differ in their
auses, pathophysiology, treatments, and outcomes (12,13)
Table 1). Careful classification of stroke type and subtype
ermitted the identification of genetic factors associated
ith CADASIL and with cerebral venous thrombosis
16,19).
amily history of stroke. In twin studies, the concordance
ates for stroke are 17.7% in monozygotic twins and 3.6% in
izygotic twins (15,20). The heritability of stroke has varied
n family studies, but allowing for some methodological
eaknesses, it appears that a family history of stroke
ncreases a subject’s stroke risk by 2- to 3-fold (21,22). In
he Framingham study, using information obtained across 3
enerations, including the original and offspring cohorts, a
arental history of stroke was associated with an approxi-
ately 2-fold increase in stroke risk: a paternal history of
troke was associated with a relative risk of 2.4 and a
aternal history with a risk of 1.4 (21). In later studies
ooking at the heritability of stroke subtypes, the large
rtery atherosclerosis and small vessel subtypes were
ound to be more commonly inherited than the cardio-
mbolic subtype (23).
Few studies have separated ischemic stroke risk from that
f intracerebral hemorrhage (ICH), probably because of the
maller frequency of the ICH stroke type and the difficulty
n retrospectively obtaining this information. It appears that
CH in a first-degree relative increases a subject’s odds by as
uch as 2- to 6-fold (24). Subarachnoid hemorrhage
SAH) has a distinct clinical profile, and a family history of
AH has been associated with an increased risk for SAH
f about 4-fold (25); because of this association, screening of
rst-degree relatives of patients with SAH is currently
ecommended (26). Evidence of a gene-environment inter-
ction with smoking, another risk factor for SAH, also may
xist for aneurysmal SAH (27).
enetic polymorphisms. Polymorphisms in 2 genes in-
rease the risk for cerebral venous thrombosis. A polymor-
Abbreviations
and Acronyms
CADASIL  cerebral
autosomal dominant
arteriopathy with
subcortical infarcts and
leukoencephalopathy
CHD  coronary heart
disease
ICH  intracerebral
hemorrhage
PAR  population-
attributable risk
RNA  ribonucleic acid
SAH  subarachnoid
hemorrhage
SNP  single-nucleotide
polymorphismhism in the gene coding for coagulation factor V results in
s
vform of factor V variant, factor V Leiden, that is resistant
o degradation by activated protein C, resulting in a hyper-
oagulable state (19). This polymorphism involves a single
ase pair substitution. The risk for cerebral venous throm-
osis is increased almost 8-fold in subjects carrying 1 copy of
he variant (28). The prothrombin G20210A polymorphism
onfers an almost 10-fold increased risk for cerebral venous
hrombosis. The risk is further magnified with the use of the
irth control pill and in the post-partum period (28). Both
f these factors may be associated with a mildly increased
isk for arterial ischemic stroke (19,28).
onogenic disorders associated with stroke. These dis-
rders are uncommon, accounting for 1% of all strokes.
hey are typically associated with stroke in childhood or
oung adulthood, with certain stroke types and subtypes,
he absence of other stroke risk factors, and with specific
henotypes of the associated diseases (Table 2).
CADASIL was initially recognized in the 1990s as an
dult-onset hereditary disorder of dementia and stroke (16),
nd its genetic and molecular basis was subsequently unrav-
led (Fig. 1). CADASIL is characterized by recurrent
ubcortical ischemic strokes starting at ages 30 to 40 years,
rogressive or stepwise cognitive decline, white matter
hanges on magnetic resonance imaging, and, in some
atients, migraine with aura and mood disturbances (29,30).
n addition to genetic analysis, skin biopsy is used to aid in
iagnosis (31).
In other monogenic disorders—such as Fabry disease
X-linked recessive inheritance), sickle-cell disease (autoso-
al dominant inheritance), and mitochondrial myopathy,
ncephalopathy, lactic acidosis, and strokelike episodes—
troke is a secondary manifestation. In Table 2, monogenic
isorders associated with stroke and vasculopathy are listed,
long with disorders associated with premature atheroscle-
osis, arterial dissection, and monogenic forms of ICH. The
eader is referred to several excellent reviews for specific
etails of these uncommon disorders (26,32,33).
ajor Stroke Types and SubtypesTable 1 Major Stroke Types and Subtypes
Type
Subtype/Presumed Major
Mechanism
Approximate
Frequency (%)
Ischemic stroke 83
Large artery atherosclerosis 14
Cardioembolism 23
Small-vessel disease 13
Other determined 3
Undetermined 30
Hemorrhagic stroke 17
Intracerebral hemorrhage Hypertension 7
Amyloid angiopathy 3
Subarachnoid hemorrhage Intracranial aneurysm 7
Cerebral venous thrombosis 1
he TOAST (Trial of Org 10172 in Acute Stroke Treatment) subtypes are commonly used to classify
schemic stroke (14). Common subtypes of hemorrhagic stroke are intracerebral hemorrhage and
ubarachnoid hemorrhage. A minority of strokes result from vascular occlusion in the cerebral
enous system, termed cerebral venous thrombosis (4–6).
GA
g
c
(
i
n
a
c
t
o
i
n
c
w
c
fi
b
r
i
a
p
9
c
(
w
i
d
r
(
(
l
i
l
1
i
r
s
T
a
w
w
l
f
r
h
i
m
s
l
t
s
M
F
C pathy; F
P X-linke
247JACC Vol. 56, No. 4, 2010 Baird
July 20, 2010:245–53 Stroke Genetics and Genomicsenomewide Association Studies
s a result of the sequencing of the human genome,
enomewide association studies may permit the detection of
ommon variant alleles (5%) of mild to moderate effect
34,35) associated with common disorders such as stroke. It
s currently believed that common stroke may result from a
umber of genes of modest effect that in combination exert
significant effect on stroke risk (36). Commercial arrays
ontaining a huge number of SNPs are now available, but
he power of a typical study of several thousand patients is
f the order of only 10% to 25% (34,35), so it is most
mportant that adequate sample sizes be studied and that
otable findings be validated and replicated in independent
ohorts. Significant amounts of time, energy, and resources
ere expended in linkage studies and association studies of
andidate genes over the past decade (37,38); many early
ndings turned out to be false positives, with studies often
eing limited by insufficient sample sizes.
The first genomewide association study in stroke was
eported from the ISGS (Ischemic Stroke Genetics Study)
n 2007 (39). No genetic locus was specifically and robustly
ssociated with stroke, but there were only about 250
atients and controls. This group went on to study the
p21.3 region (i.e., a region on the short arm [p] of
hromosome 9) that had already been associated with CHD
40,41). An association was found with stroke, although it
as not determined by genotyping that this association
onogenic Disorders Associated With StrokeTable 2 Monogenic Disorders Associated With Stroke
Disorder
Small-vessel vasculopathy
CADASIL
CARASIL
HERNS
Small-artery and large-artery vasculopathy
Fabry disease
Pseudoxanthoma elasticum
Large-artery vasculopathy
Moyamoya disease
Premature atherosclerosis
Homocystinuria
Arterial dissection
Ehlers-Danlos syndrome type IV
Marfan syndrome
Inherited cerebral amyloid angiopathies
Hereditary cerebral hemorrhage with amyloidosis of the Dutch type
Cystatin C–related familial cerebral amyloid angiopathy
Familial amyloid polyneuropathy
Cerebrovascular malformations
Autosomal dominant polycystic kidney disease
Cerebral cavernous malformations
Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)
urther details may be found in Meschia et al. (26), Ballabio et al. (32), and Rost et al. (33).
AD  autosomal dominant; AR  autosomal recessive; ATP  adenosine triphosphate; CAD
ARASIL cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalo
KD  polycystic kidney disease; TGFR2  transforming growth factor, beta receptor II; XL-R nvolved the same variants (40). Another group has since fescribed modest associations between variants in the 9p21
egion (rs2383207 and rs10757274) and ischemic stroke
42). However, in another study, 6 SNPs in the 9p21 region
including rs2383207) were found to be associated with the
arge artery atherosclerotic subtype of ischemic stroke,
ndependent of CHD and vascular risk factors (43). The
ead SNP, rs1537378, had a pooled odds ratio for stroke of
.21 and a point estimate of the PAR for atherosclerotic
schemic stroke of 20.1% (43).
In a case-control study reported in 2008 (44), the 4q25
egion was found to be associated with the cardioembolic
ubtype of ischemic stroke (with an odds ratio of about 1.5).
his locus had already been found to be associated with
trial fibrillation. An association, although to a lesser degree,
as found with all ischemic stroke (44); this latter finding
as attributed to possible undetected cases of atrial fibril-
ation in patients with cryptogenic strokes. Another locus
or cardioembolic stroke, on 16q22, has been recently
eported (45). These studies demonstrate the value of
aving accurate stroke subtype classification, although hav-
ng a standardized methodology in multicenter studies is a
ajor challenge. For intracranial aneurysms, initial and
eemingly quite robust associations have been found with
oci on 2q, 8q, and the 9p21 region (the rs10757278 variant
hat is also associated with CHD) (46,47).
The first prospective genomewide association study in
troke was reported in 2009 from the CHARGE (Cohorts
Causative Gene/Chromosome Location Inheritance Pattern
ch 3 gene AD
nown AR
1.1-p21.3 AD
a-galactosidase A gene XL-R
-binding cassette subfamily C member 6 gene AR or AD
4.2-26, 17q25 Polygenic or AR
athionine beta synthase AR
agen type III gene AD
1 and TGFR2 genes AD
loid precursor protein gene AD
atin-C gene AD
sthyretin gene AD
1, PKD2 AD
1-q22, 7p13-p15, 3q25.2-q27 AD or sporadic
oglin and activin receptor–like kinase 1 genes AD
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
BN1 fibrillin 1; HERNS hereditary endotheliopathy with retinopathy, nephropathy, and stroke;
d recessive.Not
Unk
3p2
Alph
ATP
3p2
Cyst
Coll
FBN
Amy
Cyst
Tran
PKD
7q2
End
ASIL or Heart and Aging Research in Genomic Epidemiology)
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Stroke Genetics and Genomics July 20, 2010:245–53onsortium (48). Consisting of 4 prospective epidemio-
ogical cohorts, this large study of nearly 19,600 subjects
ith 1,544 incident strokes identified 2 SNPs on chro-
osome 12, in the region of 12p13, although replication
as obtained only for the rs12425791 SNP; the hazard
atios were 1.3 for all stroke and 1.0 for ischemic stroke.
his SNP was located close to the ninjurin 2 gene, which
ncodes an adhesion molecule expressed in glia that
hows increased expression after nerve injury. Without
enotyping, it is not known if this finding is associative or
ausative. The International Stroke Genetics Consortium,
stablished in 2007, is currently validating the results of
he CHARGE study. The International Stroke Genetics
onsortium is also collaborating with the Wellcome
rust Case Control Consortium–2 in a multistage genome-
ide association study of ischemic stroke. Plans are under
ay for the development of a similar genomewide survey in
he U.S. (49).
Aside from unaccounted stroke risk, genomewide associ-
tion studies may reveal genetic bases for major stroke risk
actors themselves, which account for up to 60% of the PAR
Autosomal dominant
inheritance
Strok
Cogn
Migr
Leuk
Missen
and 86%
Figure 1 Pathophysiology of CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencep
mutations in the Notch 3 gene. This gene is located on chromosome 19, on the p
occur on exons 2 to 6 and are single-point or missense mutations. There is an ac
vasculature, particularly in the brain, the retina, and the skin.or stroke (9,10,50) (Fig. 2). These include hypertension tthe leading modifiable stroke risk factor), which has a PAR
f 30% to 40%; diabetes; smoking; atrial fibrillation; and
HD itself (with a PAR of about 4% to 5%). Loci have
een associated with atrial fibrillation (4q25 and 6q22)
44,45), diabetes (loci in and around the genes cyclin-
ependent kinase inhibitor 2A and cyclin-dependent kinase
nhibitor 2B in the 9p21 region, among others) (51), and
ypertension (serine threonine kinase 39) (52).
There has clearly been a remarkable amount of informa-
ion coming to light, and a number of loci of interest are
merging, but it is too early to tell how major an impact
enomewide association studies will turn out to have. In
tudies of other disease states, the functions of some genes
ave not conformed to known disease biology or not coded
or proteins, as expected, but rather for ribonucleic acids
RNAs), highlighting the importance of gene expression
nd of micro-RNAs as future players (34–36). It is also vital
hat these findings be replicated and that their PARs be
valuated further; loci found for some other disease states
ave been of very small effect or have had little predictive
alue after adjustment for known risk factors (36), as may be
mall vessel)
e decline, dementia
 with aura 
cephalopathy
Blood vessels:
Granular osmophilic
material in basement 
membrane 
surrounding vascular 
smooth muscle cells 
and pericytes on 
ultrastructural
examination
utations – 58% in exon 4 
exons 2-6
athy (CADASIL) is an autosomal dominant disorder resulting from a number of
) arm, at 19p13.2 to p13.1. This gene has 33 exons; the majority of mutations
tion of osmophilic granules in smooth muscle of blood vessels throughout thee (s
itiv
aine
oen
se m
 in 
halop
(short
cumulahe case for the rs10757274 polymorphism on chromosome
9
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July 20, 2010:245–53 Stroke Genetics and Genomicsp21.3 and prediction of CHD risk (53). In the future, it is
ikely that the focus will be on genotyping studies to look for
ess common variant alleles of more significant effect and in
tudying copy number variants as additional genetic factors
ssociated with common disorders such as stroke.
ene Expression Profiling,
roteomics, and Metabolomics
number of important methodologies and technologies
ave been developed in tandem to those for investigating
eoxyribonucleic acid variations, based on the fact that
eoxyribonucleic acid is transcribed to messenger RNA,
hich in turn is translated into protein and metabolites.
hese methods can be used to investigate the entire tran-
criptome (gene expression profiling or RNA expression
rofiling), the proteome (proteomics), and the metabolome
metabolomics). They capture not only functional changes
nduced by genetic variations but also changes induced by
nvironmental factors, risk factors, and the effects of inter-
entions, and they can be used to monitor functional
hanges occurring over time. The interest of these methods
or stroke is that they offer potential for identifying biomar-
ers (e.g., from the blood) that can be used in the clinic to
iagnose and monitor disease and changing risk associated
ith mutations and treatment interventions. In genome-
ide association studies, they are used to study if and to
hat degree genetic polymorphisms are functional.
ene expression profiling and signatures for stroke
lassification. Gene expression profiling has been most
idely applied in the field of oncology. Preliminary studies
ave been performed in carotid plaque specimens removed
uring endarterectomy (54).
Messenger RNA profiling of the peripheral blood has
lso been used to investigate a number of neurological
0 20 40
CHD
Stroke
Figure 2 Attributable Risks of Major Risk Factors for Stroke an
Vascular disorders, such as coronary heart disease (CHD) and stroke, share a num
attributable risk for stroke. Data were obtained from the INTERHEART (Effect of Po
study (11) using Northern American statistics and data from current guidelines forisorders, including stroke, despite initial concerns over the ipecificity of signatures obtained. Blood-derived mononu-
lear cells (monocytes and lymphocytes) are involved in the
evelopment of atherosclerotic lesions associated with many
orms of vascular disease, including stroke (55). In stroke,
eripheral blood mononuclear cells are also of significance
ecause blood-borne leukocytes, first polymorphonuclear cells
nd then subsequently mononuclear cells, are key players in the
volution of brain infarcts. The cells selectively migrate to and
nfiltrate the ischemic brain tissue. These inflammatory and
mmune cells may not only exacerbate ischemic reperfusion
njury but may also be involved in tissue repair and remodeling
fter stroke (56). Changes in functional gene expression in
eripheral blood mononuclear cells in brain disorders may
ccur in response to exposure to brain antigens (57).
Early human studies in stroke using oligonucleotide
icroarrays have been promising. Using peripheral blood
ononuclear cells, a validated and replicated gene expres-
ion signature of ischemic stroke within the first 72 h has
een identified (58). The gene expression changes seemed
o reflect an adaptive response, at least in part, to the
schemic stroke, with up-regulation of genes involved in cell
dhesion, inhibition of neuronal apoptosis, response to
ypoxia, and vascular repair (Table 3). One example is
ctonucleoside triphosphate diphosphohydrolase 1 (cluster
f differentiation 39), a prominently up-regulated gene that
s of interest for its cerebroprotective and cardioprotective
roperties. A panel of 22 genes was about 80% accurate for the
etection of ischemic stroke in an external sample (58), while
nother group found this panel to be over 85% accurate, using
hole-blood profiling (59). Signatures have since been devel-
ped for ICH (60) (prominently up-regulated genes being
mphiphysin and interleukin-1 receptor 2), stroke recovery
61), and ischemic stroke subtypes (62).
Given the increasing recognition of the role of lymphocytes
80 100
Hyperlipidemia
Smoking
Hypertension
Diabetes
Atrial fibrillation
D
f risk factors in common. CHD also accounts for 1% to 2% of the population-
ly Modifiable Risk Factors Associated With Myocardial Infarction in 52 Countries)
ry prevention of stroke (50).60
d CH
ber o
tential
priman stroke and vascular disease (63), and the improved charac-
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Stroke Genetics and Genomics July 20, 2010:245–53erization of lymphocyte subpopulations, ongoing studies are
nvestigating gene expression within leukocyte populations,
long with circulating stem cells that may be involved in tissue
epair and recovery after stroke. Real-time polymerase chain
eaction studies are proving practical in ongoing application
nd validation studies. This approach offers hope for the
evelopment of a rapid diagnostic test for stroke if a suitable
echnology platform could be identified. This work also offers
ope for the identification of gene panels for vascular disease
isk and for prediction of response to treatment.
roteomics and metabolomics. Blood-based protein bio-
arkers (64) could be of great value for the early detection
f stroke because they could permit more accurate diagnoses
o be made at the initial point of care. Currently, stroke
valuation is dependent on the patient’s being taken to the
ospital and undergoing a brain scan, which can delay the
ommencement of therapy for up to 60 to 90 min. Using a
andidate protein approach, a panel of 4 proteins showed
odest accuracy for the diagnosis of acute ischemic and
emorrhage stroke (65). The proteins were a marker of glial
ctivation (S100beta), a marker of inflammation (matrix
etalloproteinase-9), brain natriuretic factor, and D-dimer.
sing surface-enhanced laser desorption/ionization tech-
ology, apolipoprotein C-I and apolipoprotein C-III were
dentified as potential plasmatic markers to distinguish
etween ischemic and hemorrhagic stroke (66). The results
ere validated using enzyme-linked immunoabsorption as-
Classes of Genes Expressed in Peripheral WhiteTable 3 Classes of Genes Expressed in Peri
Pathophysiological Class
White cell activation and differentiation (65%)
Response to hypoxia (15%)
Vascular repair (10%)
Response to the altered cerebral microenvironment (5%)
Unknown (5%)
Classes of genes showing increased expression in peripheral blood mo
suggestive of at least a partial adaptive response to the stroke.
CD  cluster of differentiation; FcGR2A  Fc fragment of IgG, loways; further findings on clinical utility are awaited. dIn another study that used surface-enhanced laser desorp-
ion/ionization and logical analysis-of-data classification
odeling, 3 biomarkers were identified from mass spectral
eaks that could detect ischemic stroke with an accuracy of
5% (67). The results were upheld in a validation sample,
lthough the proteins were not definitively identified. The
orrelation and root mean absolute error of the logical
nalysis-of-data predictive model were superior to those of
he other statistical algorithms used. Metabolomics has not
et been applied to stroke.
harmacogenomics. Pharmacogenomic approaches have in-
luded the evaluation and identification of genetic modifiers of
linical responses to warfarin, the statin drugs, clopidogrel, and
ntihypertensive therapy (68). The goals of these approaches
re to personalize dosing and to minimize side effects.
eart–Brain Linkages
oincident with the aforementioned findings of genetic loci
nd gene expression changes of interest in stroke have been
ramatic advances in the genetics of heart and vascular
isease. A number of genetic and genomic factors already
ppear to overlap between stroke and heart and vascular
isease, contributing to all stages of disease development:
amilial predisposition (21,22), vascular risk, monogenic
asculopathies, and in genomewide association studies, for
xample, variants in and around the 9p21 region, as previously
d Cells in Ischemic Strokel White Blood Cells in Ischemic Stroke
Examples
-like receptor 2
nucleoside triphosphate diphosphohydrolase 1 (CD39)
4
rleukin-13 receptor, alpha 1
R2A
enomedullin
kotriene A4 hydrolase
chrome b-245
6 antigen (thrombospondin receptor)
mbomodulin
ronal apoptosis inhibitory protein (apoptosis inhibition)
echol-O-methyl transferase (neurotransmitter degradation)
tamine ligase (neurotransmitter degradation)
tilin (neuronal apoptotic cell death)
spholipid scramblase 1 (neurite outgrowth in neural
evelopment)
wth arrest specific 7 (neurite outgrowth)
A0146 protein
ear cells in the first 72 h of ischemic stroke (58). These changes were
IIa, receptor.Bloophera
Toll
Ecto
CD1
Inte
FcG
Adr
Leu
Cyto
CD3
Thro
Neu
Cat
Glu
Sor
Pho
d
Gro
KIA
nonuclescribed, and the leukotriene pathway (58,69) (Fig. 3). These
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July 20, 2010:245–53 Stroke Genetics and Genomicsre deserving of further study. Furthermore, the vasculopathy
f CADASIL has not been thought to involve the heart, but
n 1 series, high rates of myocardial infarction were reported
n patients with CADASIL (70). Higher rates of sudden
nexplained death in patients with CADASIL have also
een reported and have been suggested to be due to
utonomic derangement, placing patients at higher risk for
ife-threatening arrhythmias (71).
onclusions
t present, the contribution of genetic factors in stroke is
mall, involving familial predisposition, a small number of
onogenic disorders such as CADASIL, and polymor-
hisms associated with cerebral venous thrombosis. New
ssociations are now being reported in genomewide associ-
tion studies, but these need confirmation. Future work may
ell focus on genotyping, looking for rarer high-risk variant
lleles and studying copy number variants. It is especially
mportant that initial results from expression profiling of
eripheral blood leukocytes be further explored. Genomic
ethods already show particular promise for improving
troke classification. They could ultimately permit the de-
elopment of biomarkers that could be valuable for the
iagnosis, treatment, management, and assessment of not
Vascular and
Environmental Risk
Factors
Predisposition
Family h
incre
9p21 re
STK39 g
4q25 re
Vasculopathies
Coagulopathies
Collage
FBN1 an
Notch 3
Cystath
9p21.3 r
Leukotr
Stroke and CHD
Figure 3 Stroke and Heart and Vascular Disease: Genetic and
Common genetic and genomic factors appear to contribute to the development of
and overt clinical disease. Some are proven and some are putative (*), having be
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